Synthesis and cellular characterization of the detransformation agent, (-)-depudecin

Junichi Shimada, Ho Jeong Kwon, Masaya Sawamura, Stuart L. Schreiber

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: (-)-Depudecin is a fungal metabolite that reverts the rounded phenotype of NIH3T3 fibroblasts transformed with v-ras and v-src oncogenes to the flat phenotype of the nontransformed parental cells. The mechanism of action of this detransformation agent is unknown. Although depudecin appears to be an excellent molecule for probing signaling pathways that regulate changes in the cytoskeletal architecture, reagents based on depudecin are not available as it has not yet been successfully synthesized. We therefore set out to synthesize (-)-depudecin. Results: An asymmetric synthesis of (-)-depudecin has been developed. A cell staining assay has been used to reveal the ability of synthetic depudecin, but not several structural variants, to induce a flattened morphology in v-Ha-ras-transformed NlH3T3 cells.This assay also shows that depudecin induces an intricate network of actin stress fibers in these cells and in MG63 osteosarcoma cells and reveals the essential role of the epoxide and hydroxyl moieties in depudecin. Cycloheximide and actinomycin D inhibited the ability of depudecin to induce a morphological change, suggesting that both mRNA synthesis and de novo protein synthesis are required for depudecin-mediated suppression of the transformed phenotypes in ras-transformed cells. Conclusions: The synthetic procedure provides access to (-)-depudecin and could be readily modified to produce depudecin-related reagents for the identification of depudecin's cellular target(s). This target appears to be involved in the regulation of the assembly of the actin microfilament component of the cytoskeleton in mammalian cells.

Original languageEnglish
Pages (from-to)517-525
Number of pages9
JournalChemistry and Biology
Volume2
Issue number8
DOIs
Publication statusPublished - 1995 Jan 1

Fingerprint

Phenotype
depudecin
Actins
Assays
src Genes
Stress Fibers
Epoxy Compounds
Dactinomycin
Osteosarcoma
Fibroblasts
Cycloheximide
Metabolites
Cytoskeleton
Actin Cytoskeleton
Hydroxyl Radical
Cells
Staining and Labeling
Messenger RNA
Molecules
Fibers

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Shimada, Junichi ; Kwon, Ho Jeong ; Sawamura, Masaya ; Schreiber, Stuart L. / Synthesis and cellular characterization of the detransformation agent, (-)-depudecin. In: Chemistry and Biology. 1995 ; Vol. 2, No. 8. pp. 517-525.
@article{d67a1451ca01464b95baae3b33c1ee93,
title = "Synthesis and cellular characterization of the detransformation agent, (-)-depudecin",
abstract = "Background: (-)-Depudecin is a fungal metabolite that reverts the rounded phenotype of NIH3T3 fibroblasts transformed with v-ras and v-src oncogenes to the flat phenotype of the nontransformed parental cells. The mechanism of action of this detransformation agent is unknown. Although depudecin appears to be an excellent molecule for probing signaling pathways that regulate changes in the cytoskeletal architecture, reagents based on depudecin are not available as it has not yet been successfully synthesized. We therefore set out to synthesize (-)-depudecin. Results: An asymmetric synthesis of (-)-depudecin has been developed. A cell staining assay has been used to reveal the ability of synthetic depudecin, but not several structural variants, to induce a flattened morphology in v-Ha-ras-transformed NlH3T3 cells.This assay also shows that depudecin induces an intricate network of actin stress fibers in these cells and in MG63 osteosarcoma cells and reveals the essential role of the epoxide and hydroxyl moieties in depudecin. Cycloheximide and actinomycin D inhibited the ability of depudecin to induce a morphological change, suggesting that both mRNA synthesis and de novo protein synthesis are required for depudecin-mediated suppression of the transformed phenotypes in ras-transformed cells. Conclusions: The synthetic procedure provides access to (-)-depudecin and could be readily modified to produce depudecin-related reagents for the identification of depudecin's cellular target(s). This target appears to be involved in the regulation of the assembly of the actin microfilament component of the cytoskeleton in mammalian cells.",
author = "Junichi Shimada and Kwon, {Ho Jeong} and Masaya Sawamura and Schreiber, {Stuart L.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1016/1074-5521(95)90185-X",
language = "English",
volume = "2",
pages = "517--525",
journal = "Cell Chemical Biology",
issn = "2451-9448",
publisher = "Elsevier Inc.",
number = "8",

}

Synthesis and cellular characterization of the detransformation agent, (-)-depudecin. / Shimada, Junichi; Kwon, Ho Jeong; Sawamura, Masaya; Schreiber, Stuart L.

In: Chemistry and Biology, Vol. 2, No. 8, 01.01.1995, p. 517-525.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Synthesis and cellular characterization of the detransformation agent, (-)-depudecin

AU - Shimada, Junichi

AU - Kwon, Ho Jeong

AU - Sawamura, Masaya

AU - Schreiber, Stuart L.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Background: (-)-Depudecin is a fungal metabolite that reverts the rounded phenotype of NIH3T3 fibroblasts transformed with v-ras and v-src oncogenes to the flat phenotype of the nontransformed parental cells. The mechanism of action of this detransformation agent is unknown. Although depudecin appears to be an excellent molecule for probing signaling pathways that regulate changes in the cytoskeletal architecture, reagents based on depudecin are not available as it has not yet been successfully synthesized. We therefore set out to synthesize (-)-depudecin. Results: An asymmetric synthesis of (-)-depudecin has been developed. A cell staining assay has been used to reveal the ability of synthetic depudecin, but not several structural variants, to induce a flattened morphology in v-Ha-ras-transformed NlH3T3 cells.This assay also shows that depudecin induces an intricate network of actin stress fibers in these cells and in MG63 osteosarcoma cells and reveals the essential role of the epoxide and hydroxyl moieties in depudecin. Cycloheximide and actinomycin D inhibited the ability of depudecin to induce a morphological change, suggesting that both mRNA synthesis and de novo protein synthesis are required for depudecin-mediated suppression of the transformed phenotypes in ras-transformed cells. Conclusions: The synthetic procedure provides access to (-)-depudecin and could be readily modified to produce depudecin-related reagents for the identification of depudecin's cellular target(s). This target appears to be involved in the regulation of the assembly of the actin microfilament component of the cytoskeleton in mammalian cells.

AB - Background: (-)-Depudecin is a fungal metabolite that reverts the rounded phenotype of NIH3T3 fibroblasts transformed with v-ras and v-src oncogenes to the flat phenotype of the nontransformed parental cells. The mechanism of action of this detransformation agent is unknown. Although depudecin appears to be an excellent molecule for probing signaling pathways that regulate changes in the cytoskeletal architecture, reagents based on depudecin are not available as it has not yet been successfully synthesized. We therefore set out to synthesize (-)-depudecin. Results: An asymmetric synthesis of (-)-depudecin has been developed. A cell staining assay has been used to reveal the ability of synthetic depudecin, but not several structural variants, to induce a flattened morphology in v-Ha-ras-transformed NlH3T3 cells.This assay also shows that depudecin induces an intricate network of actin stress fibers in these cells and in MG63 osteosarcoma cells and reveals the essential role of the epoxide and hydroxyl moieties in depudecin. Cycloheximide and actinomycin D inhibited the ability of depudecin to induce a morphological change, suggesting that both mRNA synthesis and de novo protein synthesis are required for depudecin-mediated suppression of the transformed phenotypes in ras-transformed cells. Conclusions: The synthetic procedure provides access to (-)-depudecin and could be readily modified to produce depudecin-related reagents for the identification of depudecin's cellular target(s). This target appears to be involved in the regulation of the assembly of the actin microfilament component of the cytoskeleton in mammalian cells.

UR - http://www.scopus.com/inward/record.url?scp=0029347704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029347704&partnerID=8YFLogxK

U2 - 10.1016/1074-5521(95)90185-X

DO - 10.1016/1074-5521(95)90185-X

M3 - Article

C2 - 9383455

AN - SCOPUS:0029347704

VL - 2

SP - 517

EP - 525

JO - Cell Chemical Biology

JF - Cell Chemical Biology

SN - 2451-9448

IS - 8

ER -